ArticleCurrent oncology (Toronto, Ont.)2026
Management of Facial Immune Checkpoint Inhibitor-Induced Vitiligo with Topical Ruxolitinib: Quantitative Assessment Using a Semi-Automatic Tool.
Thomas Breakell et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.